This is a StreetInsider.com Premium Only Page

(KNTE) –

Apr 17, 2024 04:02 PM Form 15-12G Kinnate Biopharma Inc.

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Tananbaum James B.

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Krishnamohan Neha

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Epperly Melissa B,

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Rome Michael E

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Flaherty Keith T.

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: MITCHELL DEAN J

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Farzan Nima

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Smaldone Alsup Laurie

Apr 5, 2024 04:56 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Sabzevari Helen

Apr 5, 2024 04:55 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: DeSimone Jill

Apr 5, 2024 04:55 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Meltz Mark A

Apr 5, 2024 04:40 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: GORDON CARL L

Apr 5, 2024 04:34 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: OrbiMed Capital GP VIII LLC

Apr 5, 2024 04:16 PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: Foresite Capital Fund V, L.P.

Apr 5, 2024 02:15 PM Form 4 Kinnate Biopharma Inc. For: Apr 03 Filed by: Foresite Capital Management V, LLC

Apr 3, 2024 05:28 PM Form S-8 POS Kinnate Biopharma Inc.

Apr 3, 2024 05:26 PM Form S-8 POS Kinnate Biopharma Inc.

Apr 3, 2024 05:24 PM Form S-8 POS Kinnate Biopharma Inc.

Apr 3, 2024 05:23 PM Form POSASR Kinnate Biopharma Inc.

Apr 3, 2024 09:28 AM Form 8-K Kinnate Biopharma Inc. For: Apr 03

Apr 3, 2024 09:14 AM Form SC 14D9/A Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Apr 3, 2024 09:10 AM Form 25-NSE Kinnate Biopharma Inc. Filed by: Nasdaq Stock Market LLC

Apr 3, 2024 09:07 AM Form SC TO-T/A Kinnate Biopharma Inc. Filed by: XOMA Corp

Apr 3, 2024 09:00 AM XOMA Corporation Announces Closing of Tender Offer

Mar 28, 2024 04:41 PM Form 10-K Kinnate Biopharma Inc. For: Dec 31

Mar 22, 2024 05:15 PM Form SC 14D9/A Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Mar 19, 2024 04:50 PM Form SC 14D9/A Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Mar 19, 2024 04:45 PM Form SC TO-T/A Kinnate Biopharma Inc. Filed by: XOMA Corp

Mar 5, 2024 05:01 PM Form 4 Kinnate Biopharma Inc. For: Mar 01 Filed by: Krishnamohan Neha

Mar 5, 2024 05:00 PM Form 4 Kinnate Biopharma Inc. For: Mar 01 Filed by: Williams Richard Thomas

Mar 5, 2024 05:00 PM Form 4 Kinnate Biopharma Inc. For: Mar 01 Filed by: Meltz Mark A

Mar 4, 2024 05:30 PM Form SC 14D9 Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Mar 4, 2024 05:24 PM Form SC TO-T Kinnate Biopharma Inc. Filed by: XOMA Corp

Mar 1, 2024 08:54 AM Form SC14D9C Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Mar 1, 2024 08:50 AM Form 8-K Kinnate Biopharma Inc. For: Feb 27

Mar 1, 2024 08:31 AM Kinnate Biopharma (KNTE) Sells Exarafenib to Pierre Fabre Laboratories

Mar 1, 2024 08:30 AM Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories

Feb 27, 2024 04:49 PM Form SC TO-C Kinnate Biopharma Inc. Filed by: XOMA Corp

Feb 26, 2024 07:36 AM Kinnate Biopharma (KNTE) PT Raised to $2.59 at Stifel

Feb 22, 2024 04:40 PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: Foresite Capital Fund V, L.P.

Feb 21, 2024 04:13 PM Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC

Feb 21, 2024 06:04 AM Form SC14D9C Kinnate Biopharma Inc. Filed by: Kinnate Biopharma Inc.

Feb 16, 2024 12:42 PM William Blair Downgrades Kinnate Biopharma (KNTE) to Market Perform

Feb 16, 2024 09:10 AM Form 8-K Kinnate Biopharma Inc. For: Feb 16

Feb 16, 2024 08:00 AM XOMA (XOMA) to Acquire Kinnate Biopharma (KNTE) for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Feb 16, 2024 08:00 AM Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share

Feb 16, 2024 08:00 AM XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

Feb 16, 2024 07:55 AM Kinnate Biopharma (KNTE) Halted, News Pending

Feb 14, 2024 04:17 PM Form SC 13G/A Kinnate Biopharma Inc. Filed by: Nextech V Oncology S.C.S., SICAV-SIF